Pacira BioSciences, Inc. SEC filings PCRX
Pacira BioSciences, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to Mar 31, 2014. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 4, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 8, 2026 (material agreement, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SC 14D9/A | Filing | Nov 3, 2026 | — |
| SC 14D9 | Filing | Oct 30, 2026 | — |
| SC TO-T | Filing | Oct 30, 2026 | — |
| SC TO-C | Filing | Oct 8, 2026 | — |
| SC14D9C | Filing | Oct 8, 2026 | — |
| SC TO-C | Filing | Oct 8, 2026 | — |
| DFAN14A | Filing | May 28, 2026 | — |
| DFAN14A | Filing | May 21, 2026 | — |
| DFAN14A | Filing | May 20, 2026 | — |
| DFAN14A | Filing | May 13, 2026 | — |
| DEFC14A | Filing | May 12, 2026 | — |
| DFAN14A | Filing | May 12, 2026 | — |
| PRRN14A | Filing | May 8, 2026 | — |
| PRRN14A | Filing | Apr 30, 2026 | — |
| DEFC14A | Form defc14a | Apr 28, 2026 | — |
| PREC14A | Form- prec14a | Apr 17, 2026 | — |
| DFAN14A | Filing | Mar 12, 2026 | — |
| DFAN14A | Filing | Mar 11, 2026 | — |
| DFAN14A | Amendment no. 1 | Jan 9, 2026 | — |
| DFAN14A | Filing | Dec 30, 2025 | — |
| DFAN14A | Filing | Mar 14, 2025 | — |
| DFAN14A | Filing | Dec 11, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2023 | — |
| CORRESP | Letter to the SEC | Oct 6, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 22, 2023 | — |
| SC TO-T/A | Filing | Nov 19, 2021 | — |
| SC TO-T/A | Filing | Nov 18, 2021 | — |
| SC TO-T/A | Filing | Nov 12, 2021 | — |
| SC TO-T/A | Filing | Nov 1, 2021 | — |
| SC TO-T | Filing | Oct 22, 2021 | — |
| SC TO-C | Filing | Oct 12, 2021 | — |
| CT ORDER | Filing | Aug 17, 2020 | — |
| CT ORDER | Filing | Apr 10, 2020 | — |
| CT ORDER | Filing | Dec 6, 2019 | — |
| CT ORDER | Filing | Apr 15, 2019 | — |
| CT ORDER | Filing | Mar 11, 2019 | — |
| CT ORDER | Filing | Sep 12, 2017 | — |
| CT ORDER | Filing | Jun 9, 2017 | — |
| CT ORDER | Filing | Dec 23, 2016 | — |
| CT ORDER | Filing | Sep 17, 2015 | — |
| CT ORDER | Filing | Jun 22, 2015 | — |
| CT ORDER | Filing | Feb 19, 2015 | — |
| UPLOAD | Letter from the SEC | Dec 3, 2014 | — |
| CT ORDER | Filing | Nov 25, 2014 | — |
| CORRESP | Letter to the SEC | Nov 7, 2014 | — |
| UPLOAD | Letter from the SEC | Oct 27, 2014 | — |
| CT ORDER | Filing | Sep 17, 2014 | — |
| CT ORDER | Filing | Sep 8, 2014 | — |
Showing 48 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1396814
- Former names
- Pacira Pharmaceuticals, Inc. (until Apr 9, 2019); PACIRA INC (until Nov 5, 2008); Blue Acquisition Corp (until Apr 16, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.